327 related articles for article (PubMed ID: 30897538)
1. Biological mechanisms and related natural modulators of liver X receptor in nonalcoholic fatty liver disease.
Ni M; Zhang B; Zhao J; Feng Q; Peng J; Hu Y; Zhao Y
Biomed Pharmacother; 2019 May; 113():108778. PubMed ID: 30897538
[TBL] [Abstract][Full Text] [Related]
2. Nuclear receptors and nonalcoholic fatty liver disease.
Cave MC; Clair HB; Hardesty JE; Falkner KC; Feng W; Clark BJ; Sidey J; Shi H; Aqel BA; McClain CJ; Prough RA
Biochim Biophys Acta; 2016 Sep; 1859(9):1083-1099. PubMed ID: 26962021
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional Regulation of Metabolic Pathways via Lipid-Sensing Nuclear Receptors PPARs, FXR, and LXR in NASH.
Cariello M; Piccinin E; Moschetta A
Cell Mol Gastroenterol Hepatol; 2021; 11(5):1519-1539. PubMed ID: 33545430
[TBL] [Abstract][Full Text] [Related]
4. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
Serviddio G; Bellanti F; Vendemiale G
Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
[TBL] [Abstract][Full Text] [Related]
5. Liver X Receptor Inverse Agonist SR9243 Suppresses Nonalcoholic Steatohepatitis Intrahepatic Inflammation and Fibrosis.
Huang P; Kaluba B; Jiang XL; Chang S; Tang XF; Mao LF; Zhang ZP; Huang FZ
Biomed Res Int; 2018; 2018():8071093. PubMed ID: 29670908
[TBL] [Abstract][Full Text] [Related]
6. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
7. The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans.
Ballestri S; Nascimbeni F; Romagnoli D; Baldelli E; Lonardo A
Adv Ther; 2016 Mar; 33(3):291-319. PubMed ID: 26921205
[TBL] [Abstract][Full Text] [Related]
8. Targeting Liver X Receptors for the Treatment of Non-Alcoholic Fatty Liver Disease.
Kim H; Park C; Kim TH
Cells; 2023 May; 12(9):. PubMed ID: 37174692
[TBL] [Abstract][Full Text] [Related]
9. Natural PPARs agonists for the treatment of nonalcoholic fatty liver disease.
Pan J; Zhou W; Xu R; Xing L; Ji G; Dang Y
Biomed Pharmacother; 2022 Jul; 151():113127. PubMed ID: 35598367
[TBL] [Abstract][Full Text] [Related]
10. Expression of liver X receptor correlates with intrahepatic inflammation and fibrosis in patients with nonalcoholic fatty liver disease.
Ahn SB; Jang K; Jun DW; Lee BH; Shin KJ
Dig Dis Sci; 2014 Dec; 59(12):2975-82. PubMed ID: 25102981
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes.
Cernea S; Cahn A; Raz I
Expert Rev Clin Pharmacol; 2017 May; 10(5):535-547. PubMed ID: 28276774
[TBL] [Abstract][Full Text] [Related]
12. Natural modulators of liver X receptors.
Huang C
J Integr Med; 2014 Mar; 12(2):76-85. PubMed ID: 24666673
[TBL] [Abstract][Full Text] [Related]
13. Effects of Natural Products on Fructose-Induced Nonalcoholic Fatty Liver Disease (NAFLD).
Chen Q; Wang T; Li J; Wang S; Qiu F; Yu H; Zhang Y; Wang T
Nutrients; 2017 Jan; 9(2):. PubMed ID: 28146130
[TBL] [Abstract][Full Text] [Related]
14. Natural Products in the Modulation of Farnesoid X Receptor Against Nonalcoholic Fatty Liver Disease.
Wang J; Yang N; Xu Y
Am J Chin Med; 2024; 52(2):291-314. PubMed ID: 38480498
[TBL] [Abstract][Full Text] [Related]
15. Liver X Receptors Regulate Cholesterol Metabolism and Immunity in Hepatic Nonparenchymal Cells.
Endo-Umeda K; Makishima M
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31614590
[TBL] [Abstract][Full Text] [Related]
16. Liver X receptors bridge hepatic lipid metabolism and inflammation.
Liu Y; Qiu DK; Ma X
J Dig Dis; 2012 Feb; 13(2):69-74. PubMed ID: 22257474
[TBL] [Abstract][Full Text] [Related]
17. The liver X receptor: a master regulator of the gut-liver axis and a target for non alcoholic fatty liver disease.
Ducheix S; Montagner A; Theodorou V; Ferrier L; Guillou H
Biochem Pharmacol; 2013 Jul; 86(1):96-105. PubMed ID: 23542537
[TBL] [Abstract][Full Text] [Related]
18. Multi-drug approaches to NASH: what's in the development pipeline?
Johnston MP; Patel J; Byrne CD
Expert Opin Investig Drugs; 2020 Feb; 29(2):143-150. PubMed ID: 31524533
[No Abstract] [Full Text] [Related]
19. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH).
Westerouen Van Meeteren MJ; Drenth JPH; Tjwa ETTL
Expert Opin Investig Drugs; 2020 Feb; 29(2):117-123. PubMed ID: 31523999
[No Abstract] [Full Text] [Related]
20. Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease.
Puengel T; Liu H; Guillot A; Heymann F; Tacke F; Peiseler M
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
